Citations

Clear

9383 citation(s) found for "Thomas, PS".

Empowering Women in Academic Emergency Medicine: A Time‐Efficient Workshop Incorporating Large Language Models to Enhance Leadership Skills
Mishkin, Hannah, Chekijian, Sharon , Lema, Penelope C. , Binz, Nikki, Platt, Melissa , Thomas, Ynhi T. , Walker, Laura E., Werner, Sandra, Sethuraman, Kinjal , Mishkin, Hannah M , Thomas, Ynhi T , Raukar, Neha , Sethuraman, Kinjal N , Linden, Judith A. , Sun, Wendy W. , Raukar, Neha P.

Mayo Clinic

AEM Education and Training | March 17, 2026 | Volume: 10 | Issue: 2 | Pages: No page available

10.1002/aet2.70128 | PMID 42291614 Get It

ABSTRACT Background and Aims Women now comprise over half of US medical school matriculants yet remain underrepresented in academic leadership, including emergency medicine (EM). Leadership training within medical education is variable, particularly in communication, conflict management, negotiation, and operations. Concurrently, large language models (LLMs) are emerging as accessible tools to support leadership skill development. This study aimed to develop and evaluate an AI‐augmented leadership skills workshop designed to address the leadership gap for women in academic emergency medicine. Materials and Methods The Academy for Women in Academic Emergency Medicine (AWAEM) developed and piloted a leadership development workshop at the 2025 Society for Academic Emergency Medicine Annual Meeting. The curriculum integrated evidence‐based leadership frameworks with experiential small‐group learning and structured demonstrations of LLM use. Educational strategies included brief didactics, reflection on lived leadership challenges, peer discussion, and guided LLM‐supported simulation of leadership conversations. Pre‐workshop and postworkshop surveys and qualitative feedback were collected to assess participant confidence and perceived utility. Results Participants demonstrated increased confidence in navigating power‐differential conversations and initiating negotiations following the workshop. There was greater reported intent to apply leadership frameworks and to utilize LLMs for leadership‐related tasks. Qualitative feedback highlighted themes of empowerment, practical applicability, and the importance of a psychologically safe, gender‐informed learning environment. Participants identified LLMs as a novel and accessible adjunct to traditional leadership development resources. Discussion and Conclusions An AI‐augmented, experiential leadership workshop is a feasible and scalable approach to addressing persistent leadership development gaps for women in academic emergency medicine. Integrating LLM‐supported practice with established leadership frameworks may enhance learner confidence and engagement. This model offers a practical strategy to support leadership skills for women physicians needed to navigate systemic barriers and advance into leadership roles.
Survival Following Colorectal Cancer Surgery in Low‐ and Middle‐Income Countries: A Systematic Review and Meta‐Analysis
Afolaranmi, Oluwasegun, Diehl, Thomas M. , Virani, Sehar Salim , Yang, Qiuyu, Okwunze, Kenechukwu , Khan, Adel H., Mughal, Nabiha Akhlaq, Schroeder, Daniel J., Pourdashti, Sheida , Khan, S., Zafar, Syed Nabeel, Afolaranmi, Oluwasegun , Afolaranmi, Oluwasegun , Christensen, Leslie , Schroeder, Daniel, Khan, Sadaf, Zafar, Syed Nabeel

Mayo Clinic

Journal of Surgical Oncology | March 16, 2026 | Volume: 133 | Issue: 7 | Pages: 872-880

10.1002/jso.70235 | PMID 41834407 Get It

ABSTRACT Background and Objectives Surgery is the mainstay of treatment for localized colorectal cancer (CRC); however, little is known about survival outcomes following CRC surgery in low‐ and middle‐income countries (LMICs). Here, we examine the available data on long‐term outcomes following CRC resections in LMICs. Methods A systematic review and meta‐analysis were conducted on primary research studies reporting survival data after CRC resection with curative intent in LMICs. Disease‐free survival (DFS) and overall survival (OS) data were extracted, and random effects modelling was used to estimate the pooled survival rates. Results One hundred and fifty‐four studies representing 20,589 CRC patients were analyzed. Notably, only 27 (20%) of the 137 LMICs were represented in the literature. The pooled 5‐year OS estimate was 88% (95% CI: 77–95), 76% (69–81), and 57% (49–64) for Stages I, II, and III, respectively. 5‐year DFS estimates were 82% (71–90), 76% (67–84), and 59% (51–65) for stages I, II, and III, respectively. Combined OS and DFS estimates for all three stages were 76% and 69%, respectively. Survival rates varied considerably across the included studies and between income groups. Conclusions With the rising incidence of CRC globally, our work highlights the dearth of data on long‐term outcomes following CRC operations in most LMICs and emphasizes the urgent need for research capacity building.
Predominant Symptom in Gastroparesis: Relationships to Quality of Life, Treatments, and Outcome
Parkman, Henry P., Wilson, L., Grover, Madhusudan, Chumpitazi, Bruno P. , Burton‐Murray, Helen, Sarosiek, I, Moshiree, Baha, Preidis, Geoffrey A. , Shulman, R. J., Miriel, Laura , Shade, Dave, Kuo, Braden, McCallum, Richard W., Pasricha, Pankaj J. , Parkman, Henry P. , Parkman, H P , Hasler, William L. , Chumpitazi, Bruno P , Burton-Murray, Helen , Preidis, Geoffrey A , Wilson, Laura A., Grover, Madhusudan , Moshiree, Baha , Kuo, Braden , McCallum, Richard W. , Abell, Thomas L.

Mayo Clinic

Neurogastroenterology & Motility | March 16, 2026 | Volume: 38 | Issue: 3 | Pages: No page available

10.1111/nmo.70287 | PMID 41833524 Get It

ABSTRACT Background Patients with gastroparesis (Gp) can have a variety of symptoms. Apart from use of prokinetics, symptomatic therapies for the predominant symptom (PrS) are used. Aims (1) To classify Gp patients based on their PrS; (2) To determine differences in Gp symptoms, gastric emptying (GE), quality of life (QOL), treatments, and symptom improvement among Gp patients with different PrS. Methods Gp patients were enrolled in a multicenter registry and followed for 96‐weeks. Patients recorded their PrS and completed questionnaires assessing symptoms and QOL at enrollment and at follow up visits. Results Of 1013 Gp patients (361 diabetic, 607 idiopathic, 45 post‐fundoplication), the PrS were nausea (31%), vomiting (20%), abdominal pain (20%), bloating (9%), fullness (4%), GERD (4%), constipation (3%). Abdominal pain was more often a PrS in idiopathics, whereas vomiting was more often a PrS in diabetics. QOL scores were lower in the abdominal pain PrS group. PrS was associated with greater use of directed symptomatic treatment (antiemetic agents and gastric electrical stimulation for nausea and vomiting, prokinetic agents for vomiting and fullness, and constipation medications for constipation). Of 555 patients followed over 48 weeks, GCSI improved by ≥ 1 in 26% overall, more often in patients with initial PrS of nausea (32%) and bloating (35%) and less often for initial PrS of fullness (13%) or abdominal pain (15%). Conclusions In Gp patients, the most common PrS were nausea, vomiting, and abdominal pain. PrS is associated with QOL, treatments utilized, and patient outcomes. Thus, the PrS of a patient with Gp provides useful information about their present condition and future outcome.
Radiotherapy for indolent primary cutaneous B-cell lymphoma: an international multicenter ILROG analysis
Dabaja, Bouthaina S., Görlich, Dennis , Thomas, Bjorn , Sim, Van , Johnstone, P., Hashmi, Ayesha, Levis, M., Ackerson, Bradley, Hague, Christina J. , Roos, Daniel Edward, Kirova, Y., Fietkau, Rainer, Fang, Penny Q., Ng, A., Bock, Felix, Linde, Philipp , Dunst, Jürgen, Terezakis, Stephanie A, Easwaran, Teresa, Peeken, Jan C. , Wittig, Andrea, Yoon, Hong In , Illidge, Tim , Ricardi, U., Morris, S., Storck, Michael , Hoppe, Richard T, Eich, Hans Theodor, Hoppe, Richard T. , Levis, Mario , Oertel, Michael , Görlich, Dennis , Thomas, Bjorn R , Sim, Van , Levis, Mario , Weil, Christopher R , Bock, Felix , Peeken, Jan C , Yoon, Hong In , Tao, Randa , Binkley, Michael Sargent , Campbell, Belinda A , Elsayad, Khaled , Storck, Michael , Hoppe, Richard T , Hashmi, Ayesha , Weil, Christopher R. , Plastaras, John Peter , Roos, Daniel E. , Fietkau, Rainer , Fang, Penny , Tseng, Yolanda D. , Tao, Randa , Kelsey, Chris R. , Binkley, Michael S. , Eich, Hans Theodor

Mayo Clinic

Blood | March 13, 2026 | Volume: 147 | Issue: 25 | Pages: 3051-3060

10.1182/blood.2025032050 | PMID 41824381 Get It

Abstract Radiotherapy is an established treatment for low-grade primary cutaneous B-cell lymphoma. Recommendations on its use differ internationally, which prompted our group to conduct this analysis. Twenty-two institutions participated in this international study. Patient eligibility required a diagnosis of limited (T1/T2) primary cutaneous marginal zone or follicle center lymphoma treated with radiotherapy between 1995 and 2023. Data were collected retrospectively until February 2024 within the framework of the International Lymphoma Radiation Oncology Group. Overall, 535 patients were analyzed. Predominant locations were the head (40%) and trunk (36%). Radiotherapy had a median dose of 24 Gy in fractions of 2 Gy. Complete responses were observed in 91% at a median time of 3.6 months following radiotherapy. There was no statistically significant difference between treatments ≤4 Gy and >4 Gy for complete or overall response rates (P = .077 and P = .056, respectively). However, there was an inferior duration of local control with ≤4 Gy (5-year local control 73% ± 12% vs 96% ± 2%; P< .001). Radiation dose was the main prognostic factor in the univariate and multivariable Cox analysis; however, higher doses did not translate into an overall survival benefit. Toxicities rarely exceeded grade 2 but were more frequent in the >4 Gy group. Radiotherapy remains an effective treatment option for indolent skin lymphoma with low toxicity. High response rates are observed with low doses of ≤4 Gy. In comparison to conventional doses, these treatments have a shorter duration of local control but a favorable toxicity profile.
Long-term follow-up of S0221, comparing alternative dose-schedules of anthracycline and taxane therapy in early breast cancer
Barlow, William E. , Moore, Halle C F, Hobday, T., Isaacs, Claudine, Salim, Muhammad , Albain, Kathy S. , Chew, Helen K. , Burton, G., Srkalović, Gordan , Flaherty, Lawrence E. , Lew, Danika L., Hortobagyi, Gabriel N, Sharma, Priyanka, Pusztai, Lajos, Budd, George T, Moore, Halle C. F. , Isaacs, Claudine , Ali, Azka , Barlow, William E , Moore, Halle C F , Isaacs, Claudine , Albain, Kathy , Srkalovic, Gordan , McGregor, Bradley , Gralow, Julie R , Sharma, Priyanka , Pusztai, Lajos , Budd, G Thomas , Hobday, Timothy J. , McGregor, Bradley A. , Gralow, Julie R. , Hortobágyi, Gabriel N. , Sharma, Priyanka , Pusztai, Lajos , Budd, G. Thomas

Mayo Clinic

JNCI Cancer Spectrum | March 12, 2026 | Volume: 10 | Issue: 2 | Pages: No page available

10.1093/jncics/pkag024 | PMID 41832961 Get It

Abstract Background S0221 investigated weekly vs every 2 weeks dosing of doxorubicin (A) and cyclophosphamide (C) followed by paclitaxel in patients with high-risk early breast cancer. After an interim analysis, random assignment to the 2 AC arms was stopped for futility, and the trial was modified to study only the paclitaxel schedules. Methods Between December 2003 and November 2010, a total of 2716 patients were randomly assigned in a 2 × 2 factorial design to 15 weeks of weekly A and daily C vs 6 cycles of every 2 weeks AC; and weekly paclitaxel for 12 weeks vs 6 cycles of every 2 weeks paclitaxel. Between January 2011 and January 2012, an additional 578 patients were assigned to 4 cycles of every 2 weeks AC and randomly assigned to weekly vs every 2 weeks paclitaxel. Updated survival was assessed using log-rank tests and Cox regression models. We compared outcomes by breast cancer subtype as well. Results At a median follow-up of 12.1 years, there were no statistically significant differences among the 4 treatment arms in disease-free survival (DFS) (P = .91) or overall survival (P = .34) in the original protocol. Among the 578 patients assigned AC for 4 cycles and randomly assigned to paclitaxel weekly vs every 2 weeks paclitaxel, there were no overall differences in DFS (P = .32) or overall survival (P = .42). Conclusion As there were no statistically significant outcome differences in DFS or overall survival between the studied schedules of AC and paclitaxel with extended follow-up in the original or revised protocol, either paclitaxel schedule may be recommended, with selection based on toxicity, cost, or patient preference.
NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2026
Wierda, William G., Brown, Jennifer, Abramson, Jeremy, Bociek, Greg, Boyer, Daniel F. , Cortese, Matthew J , Cripe, Larry D., D’Angelo, Christopher R. , Darnell, Elijah P., Davis, Randall S. , Eradat, Herbert, Esteghamat, Naseem , Fitzgerald, Lindsey , Fletcher, Christopher D., Gaballa, Sameh , Kamdar, Manali, Kipps, Thomas J., Ma, Shuo, Nakhoda, Shazia, Schorr, Andrew, Schuster, Stephen, Seshadri, Madhav, Shanafelt, T., Ujjani, Chaitra, Wagner-Johnston, Nina, Woyach, Jennifer A. , Dwyer, Mary, Sundar, Hema, Shanafelt, Tait D. , Shanafelt, Tait D , Wierda, William G. , Abramson, Jeremy S. , Awan, Farrukh T. , Huntington, Scott F. , Kahl, Brad S. , Kamdar, Manali , Kipps, Thomas J. , Ma, Shuo, Mosse, Claudio A. , Nakhoda, Shazia , Parikh, Sameer A. , Riedell, Peter A. , Seshadri, Madhav , Siddiqi, Tanya , Sitlinger, Andrea Phillips , Thompson, Meghan C , Ujjani, Chaitra S. , Wagner‐Johnston, Nina D. , Dwyer, Mary A.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 12, 2026 | Volume: 24 | Issue: 3 | Pages: 68-80

10.6004/jnccn.2026.0012 | PMID 41825137 Get It

Bruton tyrosine kinase inhibitors (BTKis) and BCL2 inhibitor (BCL2i)–containing regimens significantly improve survival outcomes in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Results from randomized clinical trials have demonstrated that time-limited treatment with BCL2i-containing regimens resulted in higher rates of undetectable measurable residual disease (uMRD) than BTKi monotherapy or chemoimmunotherapy (CIT). Pirtobrutinib (a noncovalent BTKi) and lisocabtagene maraleucel (CD19-directed CAR T-cell therapy) are newer options for relapsed or refractory disease after prior therapy with BTKi and BCL2i-contining regimens. Histologic transformation of CLL/SLL to diffuse large B-cell lymphoma (Richter transformation) is associated with a poor prognosis. Molecular analysis to determine whether there is clonal relationship between CLL/SLL and transformed diffuse large B-cell lymphoma is useful to select an appropriate treatment option. These NCCN Guideline Insights highlight significant updates to the NCCN Guidelines for the treatment of CLL/SLL and Richter transformation.
Computers in Patient Education and Monitoring
Belda, Thomas E, Belda, Thomas E.

Mayo Clinic

Respiratory Care | March 12, 2026 | Volume: 49 | Issue: 5 | Pages: 480-488

10.4187/respcare.04490480 Get It

Practice Variability in Management of Acute Respiratory Distress Syndrome: Bringing Evidence and Clinician Education to the Bedside Using a Web-Based Teaching Tool
Belda, Thomas E, Gajic, Ognjen, Rabatin, Jeffrey T., Harrison, Barry, Belda, Thomas E., Gajic, Ognjen

Mayo Clinic

Respiratory Care | March 12, 2026 | Volume: 49 | Issue: 9 | Pages: 1015-1021

10.4187/respcare.04491015 Get It

A Web-Accessible Computer App That Can Be Used by Practitioners in Order to Determine the Acuity/Chronicity of Hypercapnia in Real-Time
Demers, Robert, Martinez, Thomas

Mayo Clinic

Respiratory Care | March 12, 2026 | Volume: 69 | Issue: 10_suppl | Pages: 4101170-4101170

10.4187/respcare.20244101170 Get It